Linkedin post from SCLP26 Nov 2025 09:09
Just out within the last few minutes. A look back over the last 12 months from Dr Callum Scott
https://www.linkedin.com/company/scancell-limited/posts/?feedView=all
Dr Callum Scott joined Scancell as Head of Development in 2024, bringing over 15 years of experience in research and development.
More than a year into the job, he has been reflecting on our progress at Scancell, how he has used previous learnings to drive our clinical development, and what sets us apart. As Callum explains, he was drawn to Scancell by our groundbreaking work in cancer immunotherapy, particularly our novel DNA ImmunoBody® platform, as well as Moditope® and antibody-based technologies.
“What sets Scancell apart is our ability to combine cutting-edge science with practical, real-world advantages that address longstanding challenges in cancer immunotherapy,” Callum says.
The team is now busy preparing for the next stage of development of the iSCIB1+ ImmunoBody® with further data from the SCOPE trial due this year, and has already manufactured, tested, and released a commercial-scale batch of drug substance suitable for clinical use. They are actively working on the necessary documents to support regulatory submissions and are maintaining close communication with the regulators to ensure success.
“While the role is fast-paced and often complex, it’s incredibly rewarding to see the team’s dedication translating into real progress toward delivering novel immunotherapies to patients,” Callum says.
hashtag#Cancer hashtag#Oncology hashtag#CancerFree hashtag#Teamwork hashtag#ImmunoBody hashtag#Immunotherapy hashtag#ClinicalDevelopment